Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors: The need for alternative strategies in the investigation of new agents in GCT Journal Article

  

Authors:	Murphy, B. A.; Motzer, R. J.; Bosl, G. J.
Article Title:	Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors: The need for alternative strategies in the investigation of new agents in GCT
Abstract:	Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated with iproplatin (CHIP). No objective responses were noted in any of the patients treated. By restricting the entry criteria to heavily pre-treated patients, the identification of new active agents in phase II trials may be hindered. Alternative strategies for the investigation of new agents in patients with GCT should be considered, particularly when studying the efficacy and relative toxicity of platinum analogues. © 1992 Kluwer Academic Publishers.
Keywords:	cancer chemotherapy; clinical article; cisplatin; advanced cancer; drug efficacy; treatment planning; antineoplastic agents; carboplatin; phase 2 clinical trial; nausea; thrombocytopenia; vomiting; drug resistance; neoplasms, germ cell and embryonal; organoplatinum compounds; germ cell tumor; teniposide; intravenous drug administration; chip; human; male; priority journal; article; cisplatin-refractory; iproplatin; support, u.s. gov't, p.h.s.
Journal Title:	Investigational New Drugs
Volume:	10
Issue:	4
ISSN:	0167-6997
Publisher:	Springer
Date Published:	1992-11-01
Start Page:	327
End Page:	330
Language:	English
DOI:	10.1007/bf00944190
PUBMED:	1336770
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027055030&doi=10.1007%2fBF00944190&partnerID=40&md5=aba3e1d2f702e84c7b4d0e3f20275e51
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/149775